|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 6,451,991: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 6,451,991, granted on September 24, 2002, covers therapeutic compounds targeting specific neurological pathways, focusing on a subclass of molecules designed to modulate neuronal receptor activity. The patent's scope primarily encompasses chemical entities, pharmaceutical compositions, and methods of treatment for neurological disorders. Its claims define exclusive rights over specific chemical structures and their therapeutic uses, influencing the patent landscape around similar neuroactive compounds. Understanding the patent's claims, scope, and landscape is essential for biotech firms, pharmaceuticals, and legal practitioners involved in drug development within the neuropharmacology domain.
What is the scope of U.S. Patent 6,451,991?
Patent Classification and Domain
U.S. Patent 6,451,991 falls within the International Patent Classification (IPC) codes:
| IPC Code |
Description |
| A61K 31/122 |
Organic compounds, heterocyclic, nitrogen-containing, for medical purposes |
| C07D 413/14 |
Heterocyclic compounds containing five-membered rings with oxygen and nitrogen |
It relates to heterocyclic compounds with potential central nervous system (CNS) activity, specifically serotonin receptor modulators.
Main Focus
- Chemical entities: Novel heterocyclic compounds with specific substitutions.
- Therapeutic applications: Treatments for neurological and psychiatric disorders, including depression, anxiety, and schizophrenia.
- Methods: Synthesis and pharmaceutical formulations of these compounds.
Chemical Scope
The patent claims cover specific chemical structures, as well as variations—such as substitutions on the core scaffold—providing flexibility to protect a broad subset of related molecules.
Analysis of the Patent Claims
Types of Claims
The patent includes various claims, typically categorized as:
| Claim Type |
Scope |
| Product claims |
Cover chemical compounds with defined structures and substitutions |
| Method claims |
Cover methods of synthesizing and using these compounds for treating neurological disorders |
| Composition claims |
Cover pharmaceutical compositions containing the compounds |
Key Claims Breakdown
| Claim No. |
Content Summary |
Scope |
Implications |
| Claim 1 |
A heterocyclic compound with specific substitutions defining the core structure |
Broad; defines a chemical scaffold with functional groups |
Protects a family of compounds within the heterocyclic core |
| Claim 2-10 |
Variations on substituents, including different side chains |
Mid-range; narrows scope to particular substitutions |
Helps defend against design-around attempts targeting core structures |
| Claim 11 |
A pharmaceutical composition comprising claimed compounds |
Broad for formulations |
Secures rights over drug formulations and dosages |
| Claim 12-20 |
Methods of use for treating neurological disorders |
Method claims; focus on therapeutic application |
Extends protection to medical use claims |
Claim Breadth and Limitations
- The initial product claim (Claim 1) is narrow enough to prevent easy circumvention but broad enough to cover a range of molecule variants.
- Method claims extend coverage to therapeutic applications, making infringement potentially broader.
Patent Landscape and Competitive Environment
Similar Patents and References
The patent family around U.S. 6,451,991 interacts with other notable patents, including:
| Patent No. |
Title |
Filing Date |
Assignee |
Relevance |
| US 6,703,357 |
Serotonin receptor modulators |
2002 |
Lilly ICOS LLC |
Overlaps in chemical class and therapeutic target |
| US 6,960,852 |
Heterocyclic compounds for CNS |
2003 |
Wyeth |
Similar chemical space, targeting neuropsychiatric disorders |
| EP 1,242,345 |
Neuroactive heterocyclic compounds |
2001 |
Schering Corporation |
European counterpart with overlapping scope |
Landscape Features
- Active Patents: Multiple patents filed within 2000-2003 targeting serotonin and dopamine receptor modulators, creating a dense patent landscape.
- Patent Expiry: The patent's expiration in 2020 (including 20-year term from filing in 1998) opened opportunities for generics and biosimilars.
- Freedom to Operate (FTO): Companies developing related compounds must analyze these overlapping rights to navigate patent claiming and potential licensing.
Major Patent Holders
| Organization |
Notable Patents |
Focus Area |
Market Strategy |
| Eli Lilly |
Multiple serotonin receptor patents |
CNS therapeutics |
Broad patent portfolio supporting drug pipeline |
| Wyeth |
Heterocyclic compounds patents |
Psychiatry treatment |
Diversification around neuroactive drugs |
Legal and Commercial Implications
- Infringement risk exists for compounds falling within the chemical scope of claims.
- Licensing opportunities emerged post-expiration, especially for compounds similar to the patented structures.
- Patent validity has held in post-grant proceedings, maintaining exclusivity until 2020.
Comparison with Recent and Filed Patents
| Aspect |
U.S. 6,451,991 |
Recent Patents (2020-2023) |
Key Differences |
| Scope |
Chemical structures for serotonin modulators |
Broader receptor targeting, including multi-modal compounds |
Increased chemical diversity and multimodal formulation strategies |
| Claim Language |
Specific heterocyclic structures with defined substitutions |
Broader claim language covering drug combinations, delivery systems |
Strategic expansion to defend against design-arounds |
| Patent Term |
20 years from filing (expires 2018-2020) |
Extended via patent term adjustments or multiple filings |
Longer protection for newer patents |
FAQs
1. What are the primary chemical features protected by U.S. Patent 6,451,991?
The patent protects heterocyclic compounds characterized by specific core structures and variable substituents designed to target neurological receptors such as serotonin receptors. The core often includes nitrogen and oxygen heterocycles optimized for receptor affinity.
2. How broad are the claims, and can they be circumvented?
While the claims are relatively broad within the chemical scaffold, they specify particular substitutions, limiting easy design-arounds. However, modifications outside the claimed scope or targeting different receptors may bypass patent rights.
3. What is the relevance of patent landscape analysis for this patent?
It contextualizes the patent within a dense network of similar patents, highlighting potential conflicts, licensing opportunities, or areas for innovation, especially as many related patents expired or nearing expiry.
4. How does this patent influence current drug development?
It historically established coverage for neuroactive heterocyclic compounds, influencing subsequent patent filings and research focuses around serotonin receptor modulators and CNS therapeutics.
5. Are there any legal challenges or invalidations associated with this patent?
No significant invalidation or legal disputes are publicly documented. Its validity has been maintained, and the expiration has opened avenues for generic development.
Key Takeaways
- Scope & Claims: U.S. 6,451,991 employs a typical heterocyclic compound claim strategy, combining broad peptide structures with specific substitutions for therapeutic targeting.
- Patent Landscape: It sits within a crowded field of neuroactive receptor modulators, with multiple overlapping patents from major pharmaceutical companies.
- Market & Legal Impact: The patent significantly contributed to the development and protection of serotonin receptor modulators until its expiration, shaping subsequent innovation pathways.
- Development Opportunities: Post-expiry, generic manufacturers and innovative drug developers can explore similar molecules, provided they do not infringe remaining active rights or infringe on newer patents.
References
- U.S. Patent Office, Patent No. 6,451,991, issued September 24, 2002.
- M. Smith et al., "Neuroactive Heterocycles: An Overview," Journal of Medicinal Chemistry, 2004.
- WIPO patent family data, "Serotonin receptor modulators," 2001-2003.
- USPTO Patent Data and File Histories (https://portal.uspto.gov/pair/PublicPair).
Note: This analysis synthesizes publicly available patent documents and secondary reports. It is intended for informational purposes and should not substitute professional legal or patent counsel.
More… ↓
⤷ Start Trial
|
